Примери за използване на Pku на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Dosing for PKU.
People with PKU should avoid aspartame.
It is also safe for people with PKU.
For the treatment of PKU, Kuvan was more effective than placebo.
The risk of the birth of sick children with PKU is 25%;
Newborns with PKU initially don't have any symptoms.
Normal levels are around 60 micromoles per litre in people without PKU.
A child with PKU is born without any manifestations of the disease.
A person with one trait for the disorder, is called a'carrier' for PKU.
The mutation that causes PKU is an autosomal recessive mutation.
Newborn blood testing identifies almost all cases of PKU.
For early detection of PKU all newborns are screened(blood test).
PKU and the other causes of hyperphenylalaninemia are inherited in a recessive fashion.
Often in untreated patients with PKU urine has a peculiar"mouse" odor.
In classic PKU, levels may range from 6 to 80mg/dl, but are usually greater than 30mg/dl.
The main study investigating Palynziq in patients with PKU consisted of different parts.
The diagnosis of PKU should be set(or rejected) not later than three weeks old child!
The recommended starting dose of Kuvan in patients with PKU is 10 mg for each kg of body weight.
PKU is caused by a genetic mutation(change to the DNA) in the human phenylalanine hydroxylase(PAH) gene.
If the family already has a sick child with PKU, the carriage of the PKU gene from the parents is obvious.
HPA and PKU are due to abnormally high levels of phenylalanine in the blood which can be harmful.
Thus, in the period of neonatal pre-treatment,a child with PKU may have unreasonable lethargy or anxiety;
PKU The usual starting dose of Kuvan in adult and paediatric patients with PKU is 10 mg for each kg of body weight.
Parents of children suffering from PKU receive medical products in medical and genetic counseling for free.
The phenylalanine-free formula provides protein andother essential nutrients in a form that is safe for people with PKU.
For the treatment of patients with PKU, Kuvan has been studied in two main studies that compared Kuvan with placebo.
The Phase III clinical development program for Kuvan included 2,randomised placebo-controlled studies in patients with PKU.
A woman who has PKU andbecomes pregnant is at risk of another form of the condition called maternal PKU.
The only effective method of treating patients with PKU is specialized diet therapy from the moment of diagnosis.
Classic PKU and the other causes of hyperphenylalaninemia affect about one of every 10,000 to 20,000 Caucasian or Oriental births.